Aehr Test Systems director Scott Geoffrey Gates sells $1.64m in shares

The market is likely over-anchoring on the backlog headline and underweighting how quickly expectations can outrun revenue recognition in a niche equipment name with a stretched multiple. For AEHR, the first-order read is positive, but the second-order effect is that any disappointment in conversion timing, customer concentration, or order cadence can compress the stock faster than the fundamentals can catch up; that matters more after a 400%+ run.

The insider sale is not dispositive by itself, but it does reinforce the idea that management may view liquidity/risk as better balanced than the market does. The bigger tell is that the equity now trades like a high-beta growth asset, so the risk is less about the reported quarter and more about whether guidance visibility holds through the next two reporting cycles. If SiC/EV capex cools even modestly, AEHR’s multiple is vulnerable before earnings power is.

Contrarian view: consensus is treating backlog as near-certain future revenue, but for capital equipment the conversion rate, customer mix, and delay risk matter more than the gross dollar figure. A better expression may be to own the broader semiconductor test/exposure basket rather than pay up for a single-name that has already rerated sharply. TGT appears irrelevant here and offers no clear read-through.

Bottom line: near-term momentum can persist, but the setup is fragile over 1-3 months if the stock fails to hold post-earnings gains; over 6-18 months, the thesis depends on sustained customer spend, not just bookings.